ArticleMolecular biology reports2026
Androgen receptor expression in glioblastoma: molecular profiling and association with tumor burden.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Androgen receptor mRNA in glioblastoma: a reliable marker of tumor burden or a statistical artefact?Molecular biology reports · 2026Article
Corrections and comments
- Commented on by
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by higher incidence and poorer outcomes in males. Increasing evidence suggests that androgen receptor (AR) expression may influence GBM progression, yet its clinical significance remains uncertain. This study aimed to evaluate AR expression at both mRNA and protein levels in GBM tissue and to explore its potential association with magnetic resonance imaging (MRI)-defined tumor volume. METHODS AND
resultsTumor samples from 34 patients with primary GBM were analyzed. AR mRNA expression was quantified by real-time PCR in 30 cases, while immunohistochemistry was performed in 24 cases to assess AR protein expression. Tumor volumes were determined from T1-contrast-enhancing and FLAIR-hyperintense MRI regions. Statistical analyses included unpaired t-tests with Welch’s corrections and Spearman’s rank correlations with additional multivariable linear regression analyses (pre-steroid imaging status was not included). Mean AR mRNA and protein expression levels were higher in males than females, though not statistically significant. AR mRNA expression showed a strong trend toward positive correlation with Ki67 proliferation index (r = 0.44, p = 0.07) and tumor volume (r = 0.36, p = 0.06 for T1-enhancing regions; r = 0.40, p = 0.03 for non-enhancing FLAIR-hyperintense regions). Exploratory multivariable model adjusted for age, sex, and MGMT status revealed that higher AR mRNA expression was independently associated with FLAIR-hyperintense tumor volume (β = 0.50, p = 0.037), while AR protein expression and all other covariates showed no significant associations.
conclusionAR expression is consistently detectable in GBM tissue and shows a trend toward association at the transcriptional level with non-contrast-enhancing tumor volume, suggesting a potential role in GBM biology and warranting further investigation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.